Church & Dwight (CHD) Q1 2026 earnings review
Surgical Portfolio Pruning Sparks Volume Surge, But Expenses Dilute the Bottom Line
Church & Dwight's painful 2025 decision to shed underperforming brands (Vitamins, Flawless, Spinbrush) is paying immediate dividends. The underlying business is accelerating: Q1 organic sales jumped 5.0%, propelled entirely by a massive 5.3% volume surge. Shedding margin-dilutive segments and bolting on premium brands like Touchland drove Adjusted Gross Margin up an impressive 130 basis points to 46.4%. However, the profit flow-through was completely absorbed by a 110-basis-point jump in SG&A (driven by Touchland amortization and ERP upgrades) and higher marketing spend. This left Adjusted Operating Income completely flat YoY ($302.6M vs $302.5M). Management's FY26 guidance projects robust EPS growth, but investors will have to wait until the back half of the year to see actual operating leverage.
🐂 Bull Case
Organic volume flipped from a -1.4% decline a year ago to +5.3% today. The consumer is heavily responding to A&H's value proposition and the premium positioning of Hero and TheraBreath.
Dropping the dead weight (VMS, Flawless) and adding Touchland permanently raised the gross margin floor, evident in the 130 bps YoY expansion that exceeded management's own expectations.
🐻 Bear Case
Adjusted gross margin soared, but Adjusted Operating Income barely budged (+0.03%). Heavy SG&A and marketing expenses consumed the entire gross profit beat.
Global organic price/mix was negative (-0.3%), with International showing a sharper -1.6% drop. The top-line beat relied entirely on volume, suggesting consumers require promotional support or are trading down in pack sizes.
⚖️ Verdict: 🟢
Bullish. The strategic portfolio reset executed in 2025 was painful but perfectly timed. Generating 5.3% volume growth in a stagnant macro environment proves the core brands are winning share. The SG&A bloat is largely tied to acquisition accounting and ERP timing, meaning real earnings leverage should materialize in H2.
Key Themes
Volume Growth is Accelerating
The most encouraging metric in the print is the 5.3% organic volume growth across the total company (Domestic +5.5%, International +5.3%, SPD +2.0%). This is a massive reversal from 25Q1 when volume was down -1.4% due to retailer destocking and weak category consumption. Management noted broad-based distribution wins and strong innovation uptake across all domestic classes of trade.
Operating Margin Stagnation (Contradicts Margin Narrative)
Despite management touting a massive 130 bps expansion in Adjusted Gross Margin (to 46.4%), the actual Adjusted Operating Margin compressed from 20.6% to 20.59%. Why? Adjusted SG&A shot up 110 bps as a percentage of sales (from 15.2% to 16.3%) due to Touchland amortization, integration costs, and an ongoing ERP project. Marketing also ticked up 20 bps. The gross margin win is real, but shareholders are not seeing it at the operating line yet.
Pricing Power Decelerating
Organic price and product mix turned negative globally (-0.3%) for the quarter, driven primarily by Consumer International (-1.6%) and Domestic (-0.1%). This represents a deceleration from prior periods where pricing offset volume declines. Management must rely purely on volume and productivity to drive growth, as the era of passing inflation to the consumer through price hikes appears completely over.
Innovation Pipeline Expanding Core Footprint
New product launches are expected to account for half of 2026 organic growth. The company is successfully executing brand extensions that stretch into entirely new sub-categories: TheraBreath launching a clinical toothpaste line, HERO launching MIGHTY SHIELD (an invisible liquid-to-patch film for daytime use) and a cleanser platform, and ARM & HAMMER pushing a new Baking Soda Fresh detergent targeted at the value tier.
Macro: Middle East and Freight Headwinds
Management explicitly flagged the fluid situation in the Middle East as creating 'some incremental volume and inflationary pressure on commodities and transportation.' While they believe these pressures are transitory and can be mitigated later in the year, Q2 gross margin guidance was capped at +50 bps specifically to account for near-term transportation cost spikes.
Acquisition Strategy Validated
The Touchland hand sanitizer acquisition is providing exactly the mix-shift management promised. It contributed to the 130 bps gross margin expansion and offset the $12.1 million domestic revenue hole left by the 2025 strategic portfolio exits. E-commerce execution also remains strong, with global online sales now representing 24% of consumer sales, up from 22.9% a year ago.
Other KPIs
Stable. Cash flow decreased slightly by $10.9 million YoY. Higher cash earnings were completely offset by an increase in working capital required to support the massive 5.3% organic volume growth. CapEx stepped up to $31.9M (from $16.5M last year), but full-year free cash flow generation remains highly secure.
Reported sales decelerated (-1.1% YoY) entirely due to the mathematical drag of shedding the VMS and Flawless businesses. However, the underlying organic growth is Accelerating rapidly (+5.4%), led by TheraBreath, Hero, and A&H Cat Litter, proving the domestic portfolio is vastly healthier today than it was 12 months ago.
Guidance
Accelerating into the back half. The midpoint implies 6.5% YoY growth. Management clearly stated that EPS growth will be weighted to H2 2026, as H1 absorbs Touchland amortization, ERP upgrade expenses, and heavy marketing investments.
Stable. The company reiterated its full-year outlook. Achieving 5.0% in Q1 means the remaining quarters only need to average ~3.0% to hit the midpoint, making this guidance look conservative and highly achievable.
Decelerating sequentially from the 5.0% print in Q1, but represents a massive improvement from the -2% to flat environment the company was navigating at this exact time last year.
Decelerating YoY (down from $0.94 in 25Q2). The company expects +50 bps of gross margin expansion to be entirely cannibalized by Touchland amortization and increased marketing/SG&A spend, compressing near-term earnings.
Key Questions
Path to SG&A Leverage
Adjusted SG&A spiked 110 bps this quarter due to Touchland amortization and the ERP project. Exactly which quarter in H2 2026 will we see these expenses roll off, and what is the normalized SG&A run-rate moving forward?
Pricing Power and Promotional Intensity
With organic price/mix turning negative globally (-0.3%), are you seeing increased promotional intensity from competitors, or is this primarily a consumer trade-down to larger, value-oriented pack sizes within your own portfolio?
Waterpik Flossers Weakness
You highlighted WATERPIK flossers as an organic sales detractor in the Domestic division. Given that you already shut down the Waterpik showerhead business last year, is the flosser business at risk of a strategic review if performance doesn't stabilize?